If you're in the life science field we invite you to subscribe to our Life Sciences Insight e-magazine Subscribe here

By Jane C. Linder, Samuel Perkins, U. Srinivasa Rangan, Philip Dover;

With its flow of new product news Genentech has earned considerable attention and is rapidly moving to the forefront of oncology, immunology and angiogenesis. What has driven this growth and made the company an industry leader? How does it manage its pipeline and decision-making process? Where is it headed for the future?

;

Many have observed that R&D investment in the life science industry is producing fewer breakthrough products in recent years. Some suggest that large companies just can't be innovative, yet there are those who are bringing out new products, so how do you foster innovation when you are already a life science industry giant? Where do the new ideas come from and how are these ideas moved forward, even when they risk cannibalizing existing business? What methods can be used to speed product development? In this the first of a two part interview we spoke to Bill Hawkins, President of Medtronic, Inc. to learn how his company successfully creates new medical device solutions each year. August 2005

Prof. Allan Cohen and Insight Staff;

Industry executives who participated in our recent Bio-Pharma program took time to participate in discussions about the future of the industry and shared their insights on the trends shaping the business. What do Industry managers believe will happen for competitive strategies, payment systems, healthcare access, global pricing issues, personalized medicine through genetics, and continuing tensions between safety and speed of approvals and product introduction? May 2005.

By Allan R. Cohen, Gaurab Bhardwaj and Ken Matsuno;

Babson Insight recently sat down with Professor Srinivasa Rangan to discuss his research on bio-pharma alliance strategies. Many of the industry's significant recent discoveries and market success have come from the combined efforts of alliance partners. Here Professor Rangan speaks about how alliances are changing the industry structure, the way companies are using alliances to grow their business, how the nature of work undertaken by an alliance can affect appropriate deal structure, and some points on the art of managing alliance relationships. click here to learn more.

Prof. Srinivasa Rangan;

Can we revolutionize healthcare with an idea that improves people’s health using products and procedures that significantly cut risk and cost, while speeding the time for recovery and in the process build a highly successful company? The answer, like the story of many disruptive innovations is a tale marked by constant challenges. Here in his own words, John Abele provides readers with a look at BSCI’s successful methods for creating new markets, building a business based on disruptive technology, how BSCI maintains its entrepreneurial spirit, and his views on trends shaping the future of patient care. May 2005

Insight Staff;

James Mullen, CEO of Biogen Idec spoke with us recently and shared his views on the impact of alliances in the Life Science industry, the challenge of fostering innovation, bridging the gap between people on the science and business sides of the company, the characteristics required to succeed in leadership roles in this changing business, and opening the industry to outside ideas and best practices found in other industries. Winter 2004.

Staff;

What do small and medium biotech and large pharmaceutical companies have to do to create and manage successful alliances? This review of research findings discusses the best practices that fit companies of various sizes and maturities, as well as examining related successful alliance strategies from Eli Lilly, Millennium and Immunicom. December 2005

Prof. Srini Rangan;

In part two of our interview with Bill Hawkins he talks about a wide range of issues facing his company and its industry. How are technology developments being made in areas beyond the medical device industry affecting research and development and product functionality? How will convergence affect the roles and relationships between pharmaceutical, biotech and medical device companies? How do you manage convergence better by improving the ability of scientists, technologists, managers and leaders to work together effectively? Read on to learn more about the views of this industry leader.Sept. 2005

;

Alliances have been changing the business of life sciences. In Babson's recent joint research project with Accenture we discovered the many changes being brought to this industry by alliances, how the players have been using alliances and what it takes to succeed. Interviewing many industry executives gave us insights into how some companies are using alliances to strengthen themselves in areas where they were weak, while others are creating entirely new strategies where they focus solely on filling a single role in the value-chain. Our report also reviews how your firm can succeed with alliances, lessons from past successes and failures, as well as the roles that various players are taking?

Jane C. Linder, Samuel Perkins, U. Srinivasa Rangan, Philip Dover;